Alpha Pro Tech (APT) Peer Comparison

$5.30

$-0.97 (-15.47%)

As on 26-Aug-2026 16:00EDT

Market cap

$53 Mln

Revenue (TTM)

$62 Mln

P/E Ratio

13.7

P/B Ratio

0.8

Div. Yield

0 %

Edit

	Alpha Pro Tech (APT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Market cap ($ Mln)	53	12,753	10,906	9,762	10,222
Revenue ($ Mln)	62	1,505	613	2,589	785
Net Profit ($ Mln)	4.20	160.59	-188.05	222.40	41.54
Net Margin (%)	6.79	10.67	-30.68	8.59	5.29
RoE (%)	6.60	10.86	-28.10	3.04	1.97
Price to Earnings	13.71	79.35	--	44.47	251.57
Price-To-Book	0.85	8.41	16.38	1.26	4.84

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Alpha Pro Tech (APT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Operating Revenue	61.91	1,504.87	612.84	2,589.30	785.10
Cost of Revenue	38.40	483.98	127.96	1,245.50	384.30
Gross Profit	22.54	942.44	393.22	1,343.60	347.62
Operating Expenses	18.87	833.56	565.37	1,108.90	335.50
Operating Profit (EBIT)	4.64	187.34	-80.49	235.00	65.30
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	5.56	203.83	-192.83	350.40	52.15
Provision for Tax	1.35	43.24	-4.79	128.00	10.61
Profit after Tax (Net Income)	4.20	160.59	-188.05	222.40	41.54
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	1.67	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	Alpha Pro Tech (APT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Shareholder's Funds	64.92	1,530.77	682.49	7,173.90	2,112.03
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	7.25	210.18	135.71	2,116.80	705.49
Current Liabilities	3.18	233.78	102.33	961.30	132.66
Total Liabilities	74.13	1,826.52	893.49	10,576.50	2,949.70

Assets ($ Mln)

	Alpha Pro Tech (APT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Non-Current Assets	21.15	630.60	404.74	7,231.50	1,749.63
Current Assets	54.19	1,344.12	515.78	3,020.50	1,200.55
Total Assets	74.13	1,826.52	893.49	10,576.50	2,949.70
Total Debt*	7.62	212.71	102.84	1,203.70	690.94
Net Current Assets	51.01	1,110.35	413.45	2,059.20	1,067.90

Cashflow ($ Mln)

	Alpha Pro Tech (APT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Cash From Operating Activities	2.37	238.66	-46.34	532.20	117.42
Cash Flow from Investing Activities	-0.64	-404.59	-77.61	-189.70	-298.47
Cash from Financing Activities	-3.38	26.53	11.89	-283.20	-15.21
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Alpha Pro Tech (APT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
ROCE (%)	5.00	11.76	-22.53	8.98	1.79
ROE (%)	6.60	10.86	-28.10	3.04	1.97
ROA (%)	5.43	7.95	-18.00	2.02	1.36
EBIT Margin (%)	8.03	13.63	-30.58	-5.99	9.87
Net Margin (%)	6.79	10.67	-30.68	8.59	5.29
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Alpha Pro Tech (APT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Revenue Growth (%)	5.71	17.55	41.55	1.37	16.49
EBIT Growth (%)	9.03	17.49	-116.42	-131.06	920.91
Net Profit Growth (%)	17.84	8.72	-102.66	-30.32	400.42
EPS Growth (%)	22.79	8.12	-96.88	-29.66	394.30
Book Value Growth (%)	6.95	17.33	-12.65	2.19	2.16

Valuation Ratios

	Alpha Pro Tech (APT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Price / Earnings	13.27	68.93	-34.59	--	189.42
Price / Book Value	0.75	8.58	9.90	--	4.40
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	6.75	53.25	-43.50	--	55.90
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Alpha Pro Tech (APT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debt to Equity	0.00	0.00	0.00	0.11	0.26
Short term debt to equity ratio	0.02	0.01	0.00	0.06	0.01
Current Ratio	17.04	5.75	5.04	3.14	9.05
Quick Ratio	11.18	3.86	4.46	2.33	7.64
Interest Coverage	--	157.91	-38.31	8.18	3.36

Operating Efficiency Ratios

	Alpha Pro Tech (APT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debtors to sales (%)	17.99	12.65	22.67	17.06	20.09
Asset Turnover	0.80	0.74	0.59	0.24	0.26
Receivable days	36.53	46.54	60.95	65.39	72.41
Inventory Days	231.15	331.92	193.84	221.09	146.53
Payable days	16.40	26.16	60.19	37.02	29.05
Cash Conversion Cycle	251.27	352.30	194.60	249.46	189.88

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly